Alcobra tumbles on Phase III ADHD results for metadoxine
This article was originally published in Scrip
Executive Summary
Alcobra's stock value was cut in half and then some on 6 October after the company revealed highly anticipated results from the first Phase III clinical trial for extended-release metadoxine (MDX) in the treatment of attention deficit hyperactivity disorder (ADHD).
You may also be interested in...
Alcobra Ends Development Of MDX For Adult ADHD, Ponders Strategic Direction
Failing to meet the primary endpoint in its second Phase III study in adult ADHD, the Israeli firm confirms there is no path forward in that indication. Developing MDX for Fragile X syndrome and business development options are under consideration.
Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.